================================================================================
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended April 30, 1999
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from: ________________ to _______________
Commission file number: 0-5958
MERIDIAN MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
Delaware 52-0898764
------------------------------ ------------------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
10240 Old Columbia Road, Columbia, Maryland 21046
- ------------------------------------------- ------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 410-309-6830
---------------
</TABLE>
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
YES [X] NO [ ]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
<TABLE>
<S> <C>
Class Outstanding as of June 14, 1999
- -------------------------------------------- -------------------------------
Common Stock, $.10 par value 2,994,930 Shares
</TABLE>
================================================================================
<PAGE>
<TABLE>
<CAPTION>
Page No.
--------
<S> <C>
PART I. FINANCIAL INFORMATION
- ------------------------------
ITEM 1. Consolidated Financial Statements (Unaudited except July 31, 1998 balance sheet)
Consolidated Balance Sheets as of
April 30, 1999 and July 31, 1998................................................................. 4
Consolidated Statements of Operations for
the Three and Nine Months Ended April 30, 1999 and 1998 ......................................... 5
Consolidated Statements of Cash Flows for
the Nine Months Ended April 30, 1999 and 1998 ................................................... 6
Notes to Consolidated Financial Statements.......................................................... 7
ITEM 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations............................................................. 8
PART II. OTHER INFORMATION
- --------------------------
ITEM 6. Exhibits and Reports on Form 8-K........................................................................ 11
SIGNATURES........................................................................................................ 12
</TABLE>
2
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
MMT's business plan is to operate as a medical device company focusing on Home
Healthcare and Emergency Medical Technologies. The Company has three areas of
business. The Drug Delivery Systems business capitalizes on injectable drug
delivery devices with an emphasis on commercial auto-injectors. This group also
supplies customized drug delivery system designs, pharmaceutical research and
development, and sterile product manufacturing to pharmaceutical and
biotechnology companies. The Government Systems business focuses on the
worldwide market for auto-injectors used by military and civil defense personnel
for self-administration of nerve agent antidotes, morphine and diazepam. The
Cardiopulmonary Systems business focuses on non-invasive cardiac diagnostics and
telemedicine. It is proceeding on schedule with the implementation of the PRIME
ECG(TM) program, an 80-lead cardiac mapping system for rapid and improved
diagnostic accuracy of cardiac ischemia.
Certain statements in this Quarterly Report on Form 10-Q are forward-looking and
are identified by the use of forward-looking words or phrases such as "will be
positioned", "expects", is or are "expected", "anticipates", and "anticipated".
These forward-looking statements are based on the Company's current
expectations. Because forward-looking statements involve risks and
uncertainties, the Company's actual results could differ materially. In addition
to the factors discussed generally herein, among the factors that could cause
results to differ materially from current expectations are: (i) the general
economic and competitive conditions in markets and countries where the Company
and its subsidiaries offer products and services; (ii) changes in capital
availability or costs; (iii) fluctuations in demand for certain of the Company's
products, including changes in government procurement policy; (iv) technological
challenges associated with the development and manufacture of current and
anticipated products; (v) commercial acceptance of auto-injectors and
competitive pressure from traditional and new drug delivery methods; (vi) the
Company's continuing ability to obtain modifications or waivers with respect to
certain financial covenants in its debt agreements; (vii) delays, costs and
uncertainties associated with government approvals required to market new drugs
and medical devices; (viii) costs of the Company's EpiPen voluntary recall
and/or EpiEZPen voluntary product exchange associated with differences from
management's estimate of the number of returned units, total costs or adverse
impact on future sales; (ix) success and timing of cost reduction programs; (x)
adequacy of product liability insurance; (xi) factors related to PRIME ECG
including successful product completion, degree of market acceptance and ability
to obtain strategic alliances; (xii) changes in the Medicare and private medical
insurance reimbursement and payment policies applicable to existing products and
products under development; (xiii) ability of competitors to design around the
Company's patent protection; and (xiv) factors relating to Year 2000 issues.
3
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
MERIDIAN MEDICAL TECHNOLOGIES, INC.
-----------------------------------
CONSOLIDATED BALANCE SHEETS
---------------------------
(In thousands, except share data)
---------------------------------
<TABLE>
<CAPTION>
April 30, July 31,
Assets 1999 1998
------ -------------- -------------
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 113 $ 284
Restricted cash 277 271
Receivables, less allowances of $356 and $325, respectively 9,144 6,787
Inventories 6,998 8,612
Deferred income taxes 1,661 1,661
Other current assets 803 681
---------- ----------
Total current assets 18,996 18,296
---------- ----------
Property, plant and equipment 20,948 19,914
Less - Accumulated depreciation 5,081 3,525
---------- ----------
Net property, plant and equipment 15,867 16,389
---------- ----------
Deferred financing fees 782 836
Capitalized software costs 1,503 545
Excess of cost over net assets acquired, net 7,669 8,325
Other intangible assets, net 2,009 2,456
---------- ----------
Total assets $ 46,826 $ 46,847
========== ==========
Liabilities and Shareholders' Equity
------------------------------------
Current liabilities:
Accounts payable and other accrued liabilities $ 5,065 $ 7,255
Note payable to bank - line of credit 7,515 3,988
Customer deposits 554 221
Current portion of long-term debt 1,533 786
---------- ----------
Total current liabilities 14,667 12,250
---------- ----------
Long-term debt - notes payable, net of discount 17,772 18,453
Long-term debt - other 81 397
Deferred income taxes 1,769 1,769
Other non-current liabilities 782 640
Shareholders' equity:
Common stock (voting and non-voting)
Par value $.10 per share; 18,000,000 shares authorized;
2,994,930 and 2,990,930 shares issued and outstanding 299 299
Additional capital 32,116 32,083
Cumulative translation adjustment 210 (15)
Accumulated deficit (20,552) (18,711)
Unearned stock option compensation (105) (105)
Treasury stock, at cost (213) (213)
---------- ----------
Total shareholders' equity 11,755 13,338
---------- ----------
Total liabilities and shareholders' equity $ 46,826 $ 46,847
========== ==========
The accompanying notes are an integral part of these consolidated financial statements.
</TABLE>
4
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
MERIDIAN MEDICAL TECHNOLOGIES, INC.
------------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
-------------------------------------
(In thousands, except per share data)
-------------------------------------
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
April 30, April 30,
1999 1998 1999 1998
---- ---- ---- ----
<S> <C> <C> <C> <C>
Net sales $ 9,620 $ 13,430 $ 30,294 $ 34,796
Cost of sales 7,937 8,324 22,032 21,220
---------- --------- ------------ -------------
Gross profit 1,683 5,106 8,262 13,576
Selling, general, and administrative expenses 1,214 1,735 4,593 4,676
Research and development expenses 278 491 875 1,266
Depreciation and amortization 817 870 2,637 2,635
Product recall --- 2,244 --- 2,244
---------- --------- --------- -------------
2,309 5,340 8,105 10,821
---------- --------- --------- -------------
Operating (loss) income (626) (234) 157 2,755
Other (expense) income:
Interest expense (812) (694) (2,479) (2,083)
Other income (expense) 107 (13) 483 181
---------- ---------- --------- -------------
(705) (707) (1,996) (1,902)
---------- ---------- ---------- --------------
Loss before income taxes (1,331) (941) (1,839) 853
Provision for income taxes --- (223) --- 317
---------- ---------- --------- -------------
(Loss) income before extraordinary loss (1,331) (718) (1,839) 536
Extraordinary loss due to extinguishment of
debt, net of income taxes of $317 --- 494 --- 494
---------- --------- --------- -----------
Net (loss) income $ (1,331) $ (1,212) $ (1,839) $ 42
========== ========== ========== ===========
Earnings per common share:
(Loss) income before extraordinary item (.44) (.24) (.61) .18
Extraordinary charge --- (.17) --- (.17)
---------- ----------- ---------- ------------
Net (loss) income per common share $ (.44) $ (.41) $ (.61) $ .01
=========== =========== ========== ===========
Earnings per common share assuming dilution:
(Loss) income before extraordinary item (.44) (.24) (.61) .16
Extraordinary charge --- (.17) --- (.15)
---------- ----------- ---------- -----------
Net (loss) income per common share assuming
dilution $ (.44) $ (.41) $ (.61) $ .01
=========== =========== =========== ==========
Weighted average shares:
Basic 2,995 2,973 2,993 2,966
Diluted 2,995 2,973 2,993 3,221
The accompanying notes are an integral part of these consolidated financial statements.
</TABLE>
5
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
MERIDIAN MEDICAL TECHNOLOGIES, INC.
-------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
-------------------------------------
(In thousands)
--------------
<TABLE>
<CAPTION>
Nine Months Ended
April 30,
1999 1998
---- ----
<S> <C> <C>
OPERATING ACTIVITIES:
Net (loss) income $ (1,839) $ 42
Adjustments to reconcile net (loss) income to net
cash (used for) provided by operating activities:
Depreciation and amortization 2,637 2,635
Amortization of notes payable discount and deferred
financing fees 164 932
Loss on fixed asset disposal --- 22
Extraordinary loss due to extinguishment of debt --- 811
Changes in assets and liabilities
Receivables (2,357) (978)
Inventories 1,614 (2,393)
Other current assets (122) (500)
Accounts payable and other accrued liabilities (1,715) 1,806
Other 245 (72)
------------ --------------
Net cash (used for) provided by operating activities (1,373) 2,305
INVESTING ACTIVITIES
Purchase of fixed assets (1,034) (2,165)
Capitalized software costs (958) ---
Increase in restricted cash (6) ---
------------- -------------
Net cash used for investing activities (1,998) (2,165)
FINANCING ACTIVITIES
Net proceeds from line of credit 3,527 (2,056)
Proceeds from refinanced notes payable long term --- 14,070
Payment on notes payable long-term --- (11,973)
Net payment on other long-term debt (330) (324)
Proceeds from issuance of warrants --- 930
Payment of deferred financing fees (30) (729)
Proceeds from issuance of common stock 33 198
------------ -------------
Net cash provided by financing activities 3,200 116
------------ -------------
Net (decrease) increase in cash (171) 256
Cash at beginning of period 284 23
------------ -------------
Cash at end of period $ 113 $ 279
========== ===========
The accompanying notes are an integral part of these consolidated financial statements.
6
</TABLE>
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. In the opinion of management, the accompanying unaudited consolidated
financial statements contain all adjustments (consisting of normal
recurring accruals) necessary to present fairly the Company's financial
position as of April 30, 1999 and July 31, 1998, the results of its
operations for the three-month and nine-month periods ended April 30, 1999
and 1998, and its cash flows for the nine-month periods ended April 30,
1999 and 1998. The results of operations for the three-month and nine-month
periods ended April 30, 1999 are not necessarily indicative of the results
that may be expected for the fiscal year ending July 31, 1999. Certain
prior period amounts have been reclassified to conform to current period
presentation.
2. Inventories consisted of the following:
<TABLE>
<CAPTION>
April 30, July 31,
--------- --------
1999 1998
<S> <C> <C>
Components and subassemblies $ 5,347 $ 6,616
Work in process 2,162 2,262
Finished goods 256 193
------------ ------------
7,765 9,071
Less: inventory valuation allowance (767) (459)
------------ ------------
$ 6,998 $ 8,612
============ ============
</TABLE>
3. In June 1997, the Financial Accounting Standards Board issued Statement
No. 130, Reporting Comprehensive Income, which was adopted by the
Company in its October 1998 financial statements. This Statement
establishes standards for reporting and display of comprehensive income
and its components. In accordance with the Statement, a reconciliation
of net income to comprehensive income is as follows:
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
April 30, April 30,
1999 1998 1999 1998
---- ---- ---- ----
<S> <C> <C> <C> <C>
Net income (loss) $ (1,331) $ (1,212) $ (1,839) $ 42
Foreign exchange translation adjustment (2) 31 225 105
---------- ---------- --------- ---------
Comprehensive income $ (1,333) $ (1,181) $ (1,614) $ 147
========== ========== ========= =========
</TABLE>
4. During the quarter ended April 30, 1999, the Company capitalized $262,000
of software development costs related to a product under development,
bringing the total capitalized to $1,503,000.
7
<PAGE>
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
The Quarter and Nine Months in Review
MMT reported a net loss of $1,331,000, $(0.44) basic and diluted earnings per
share on sales of $9.6 million for the quarter ended April 30, 1999, the third
quarter of fiscal 1999. This compares with a net loss of $1,212,000, $(0.41)
basic and diluted earnings per share, on sales of $13.4 million in the same
period of fiscal 1998, which included a $2.2 million recall expense and an
extraordinary loss due to debt extinguishment of $494,000. On a year-to-date
basis, MMT reported a net loss of $1,839,000, $(.61) basic and diluted earnings
per share on sales of $30.3 million, compared with net income of $42,000, $0.01
basic and diluted earnings per share, on sales of $34.8 million in the same
period of fiscal 1998. The results for the current quarter and year-to-date as
compared to the prior year reflect the impact of the indirect costs and
diminished sales resulting from the shipment of free EpiPen units associated
with the Class I product recall announced on May 8, 1998. While unfavorable, the
Company estimates that, excluding the effects of the EpiPen recall, fiscal 1999
year-to-date revenues would have been comparable to the same period of fiscal
1998, and that the Company would have been profitable. As outlined below, the
Company's other areas of business are operating at favorable levels on a
year-to-date basis to the same period in 1998.
Revenues of MMT's three areas of business and total gross profit for the
three-month and nine-month periods ended April 30, 1999 and 1998 are as follows:
<TABLE>
<CAPTION>
Three months ended April 30, Nine months ended April 30,
($thousands) 1999 1998 1999 1998
---- ---- ---- ----
<S> <C> <C> <C> <C>
Drug Delivery Systems $ 2,249 $ 4,493 $ 9,730 $ 15,869
Government Systems 6,736 8,623 19,317 18,083
Cardiopulmonary Systems 635 314 1,247 844
----------------- ----------------- ----------------- -----------------
Total Revenues 9,620 13,430 30,294 34,796
================= ================= ================= =================
Gross Profit $ 1,683 $ 5,106 $ 8,262 $ 13,576
================= ================= ================= =================
Gross Profit % 17.5% 38.0% 27.3% 39.0%
</TABLE>
Drug Delivery Systems business revenue in the fiscal third quarter ended April
30, 1999 was $2.2 million, $2.2 million lower than in the comparable prior year
period. The 50% decrease in revenue resulted from lower sales of EpiPens.
Reduced sales are heavily influenced by the continued supply of free EpiPens to
replace products returned and to reimburse for cash costs incurred by the
distributor as a result of the May 8, 1998 product recall. Year-to-date revenues
were $9.7 million for the nine months ended April 30, 1999, compared to $15.9
million for the same period in the prior year. The Company has supplied $1.9
million and $7.3 million of free EpiPens during the three and nine months ended
April 30, 1999, respectively, and has determined that the obligations relating
to the recall have been substantially satisfied as of April 30, 1999. The sales
of EpiPen are expected to return to pre-recall levels in the fourth quarter of
fiscal 1999.
Year to date activities of the Drug Delivery Systems business included a
continuation of the FDA approval process for generic drugs under the alliance
with Mylan Laboratories with revenues anticipated to start during fiscal 1999.
The ANDA's for Acyclovir and Diltiazem were received in February and May, 1999,
respectively, and the Company expects the ANDA for Butorphanol in the future.
During the quarter, the Company received approval from the U.S. Food and Drug
Administration (FDA) for diltiazem HCl injection, a generic injectable drug for
the treatment of heart disease. The new product is part of a line of generic
injectable drugs to be developed and manufactured by the Company and marketed by
Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories, a major
pharmaceutical company.
Government Systems revenues were $6.7 million in the third quarter of fiscal
1999 compared to $8.6 million in the prior year comparable period. Year-to-date
Government Systems revenues were $19.3 million, compared to
8
<PAGE>
$18.1 million in the prior year. The quarterly decrease in revenues resulted
primarily from the timing of sales to the USDoD, reflecting procurements for
military readiness. Fiscal 1999 second quarter sales were 92% higher than fiscal
1998 second quarter, which caused a timing difference between the second and
third quarters. Civil defense revenues of $98,000 were achieved in the current
quarter compared to no revenues in last year's fiscal third quarter.
The Company continued contract negotiations with the USDoD for renewal of its
Base Maintenance contract. Similar to the last renewal in 1995, the contract was
extended to allow continuation of procurements while the three-year renewal
contract is being finalized. Progress continued toward implementation of the MA
(multi-chambered auto-injector) project, which will provide for production of a
two-chambered auto-injector. Construction of clean room facilities for this
project has started in the fiscal third quarter. Inquiries and orders continued
to build momentum in the civil defense area, with orders received from various
municipalities for fiscal 1999 shipments.
During the quarter, the Company was given licensing approval by the Medicines
Control Agency for the Company's United Kingdom subsidiary to supply the U.K.
Ministry of Defense with a morphine auto-injector for use by military and
emergency medical personnel in the immediate management of pain. In addition to
the United Kingdom, the Company plans to use the approval to seek licensing
under the European Mutual Recognition Procedures to supply the new product to
allied armed forces throughout the continent.
Cardiopulmonary Systems revenues were $635,000 in the current year fiscal third
quarter compared to $314,000 in the prior year. The higher revenues reflected
the introduction of a new ECG monitor called the CardioPocket, which has
received 510(k) approval from the US FDA, and sales have begun in Israel, as
well as increased sales of the CardioBeeper. On a year-to-date basis, revenues
of $1,247,000 for the first nine months of fiscal 1999 were 48% higher than the
revenues of $844,0000 for the same period of fiscal 1998. This increase is
primarily the result of CardioPocket sales in the second and third quarters.
Progress continues on the PRIME ECG advanced electrocardiac mapping system, and
on January 7, 1999, the Company received CE Mark approval from health
authorities in Europe for marketing the system. The PRIME ECG system has been
studied in more than 3,000 patients in Europe, and U.S. clinical trials are
expected to begin in the coming months. The Company plans to submit an
application to the U.S. FDA in calendar 1999 for approval to market the product
in the United States. The Company is continuing active discussions with
potential marketing partners for the United States, Europe and worldwide.
The Company initiated a renovation and upgrade of its clean room manufacturing
facility during the quarter in preparation for the manufacturing and launch of
the new multi-chambered auto-injector. This planned activity resulted in the
temporary closure of its sterile filling facility and resulted in unabsorbed
plant overheads being charged in the quarterly cost of sales. This burden, in
addition to the previously mentioned impact of shipping free EpiPens, decreased
gross margins to $1.7 million or 17.5% of revenues during the third quarter of
1999, compared to $5.1 million or 38.0% for the same period of the prior year.
On a year-to-date basis, gross profit of $8.3 million or 27.3% of revenues in
1999 compares to $13.6 million or 39.0% in 1998. The Company expects the gross
profit percentage to return to pre-recall levels during the fourth quarter of
the current fiscal year.
Operating costs were $2.3 million in the fiscal 1999 third quarter, as compared
to $3.1 million for the same period last year, excluding the $2.2 million recall
in the third quarter of 1998. For the first nine months of the fiscal year,
operating costs were $8.1 million compared to $8.6 million last year, excluding
the recall. Selling, general and administrative expenses (SG&A) were $521,000
lower for the quarter due, in part, to cost cutting measures implemented in the
second quarter of fiscal 1999. On a year to date basis, lower third quarter
costs were offset by first and second quarter consulting expenses associated
with the quality systems review. During the first nine months of fiscal 1999,
the Company capitalized PRIME software development costs amounting to $958,000,
since technological feasibility was established in December 1997.
9
<PAGE>
Interest expense was $812,000 in the second quarter of fiscal 1999, and $2.5
million year-to-date. This compares to $694,000 in the third quarter of fiscal
1998, and $2.1 million year-to-date. The increased cost for both the quarter and
year-to-date reflects higher long-term debt and increased borrowings on the
working capital line of credit.
Other income was $107,000 for the quarter ended April 30, 1999, compared to
other expense of $13,000 for the same period prior year. Year to date other
income was $483,000 for fiscal 1999 and $181,000 for 1998. The increase for the
quarter and year to date was primarily the result of a grant received by the
Industrial Development Board of Northern Ireland, which totaled $86,000 for the
third quarter and $309,000 year to date.
No tax benefit has been provided on fiscal 1999 year-to-date because of the
Company's net operating loss carryforward position.
Liquidity and Capital Resources
Total cash as of April 30, 1999 was $113,000, a decrease of $171,000 from the
prior year ended July 31, 1998. The Company used $1.4 million of cash for
operations in the first nine months of fiscal 1999 attributable to temporarily
higher accounts receivable, which included sales made just prior to the end of
the quarter. This use of cash was partially offset by a further reduction of
inventory which the Company has focused on during the current fiscal year
without impacting deliveries. Investing activities in the nine months of fiscal
1999 used $2.0 million of cash for capital additions and capitalized software
costs. Financing activities generated $3.2 million, primarily from borrowings on
the asset based working capital line of credit from ING CAPITAL. During the
first quarter, the Company increased its asset based working capital line of
credit maximum availability to $8.5 million from $6.5 million. In connection
with the increased working capital line of credit with ING CAPITAL, capital
expenditures in fiscal 1999 have been limited to $3.0 million. Availability
under the working lines of credit was $1.3 million at April 30, 1999, which is
expected to increase due to the collection of receivables subsequent to
quarter-end. The Company is currently in the process of obtaining waivers of
certain debt covenants from its lenders due to the continued impact of the
EpiPen recall on revenues. As certain debt covenants are measured on a rolling
twelve-month basis, the Company expects to require waivers of those covenants in
future periods based on the current agreements.
Working capital at April 30, 1999 was $4.3 million, down from $6.0 million at
July 31, 1998. The decrease was primarily attributable to higher receivables
($2.4 million), offset by lower inventories ($1.6 million) higher current
liabilities ($4.1 million) mostly from increased borrowings on the credit lines.
Year 2000
The Company is continuing to pursue its program to address the Year 2000(Y2K)
issue as outlined in its Form 10-K for the year ended July 31, 1998. As of the
date of this filing, all of the Company's systems have a completed plan and are
Y2K compliant, with the exception of Component vendors and Programmable Logic
Controllers (PLCs). Component vendors have submitted formal documentation to the
Company concerning their Y2K readiness and a response/risk assessment is being
performed to evaluate vendor readiness. The risk assessment will be completed in
July 1999 and FY-2000 inventory/WIP recommendations will be made to management,
based on the sales forecast. PLC upgrades to attain Y2K compliance are now in
progress and are scheduled to be completed by September 1999.
Systems with completed plans and which are Y2K compliant have successfully
completed their internal Y2K validation process.
10
<PAGE>
PART II - OTHER INFORMATION
ITEM 6. Exhibits and Reports on Form 8-K:
(a) Exhibits
Exhibit 27 Financial Data Schedule
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the three months ended April
30, 1999.
11
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this Form 10-Q for the quarterly period ending April
30, 1999 to be signed on its behalf by the undersigned thereunto duly
authorized.
MERIDIAN MEDICAL TECHNOLOGIES, INC.
Registrant
June 14, 1999 By: /S/James H. Miller
Date -------------------
James H. Miller
President and
Chief Executive Officer
(Principal Executive Officer)
June 14, 1999 By: /S/Dennis P. O'Brien
Date ----------------------
Dennis P. O'Brien
Vice President-Finance
and Chief Financial Officer
(Principal Financial and
Accounting Officer)
12
<TABLE> <S> <C>
<ARTICLE> 5
<CIK> 0000095676
<NAME> Meridian Medical Technologies, Inc.
<MULTIPLIER> 1,000
<CURRENCY> U.S. Dollars
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JUL-31-1999
<PERIOD-START> FEB-01-1999
<PERIOD-END> APR-30-1999
<EXCHANGE-RATE> 1
<CASH> 390
<SECURITIES> 0
<RECEIVABLES> 9,500
<ALLOWANCES> (356)
<INVENTORY> 6,998
<CURRENT-ASSETS> 18,996
<PP&E> 20,948
<DEPRECIATION> (5,081)
<TOTAL-ASSETS> 46,826
<CURRENT-LIABILITIES> 14,667
<BONDS> 17,772
0
0
<COMMON> 299
<OTHER-SE> 11,456
<TOTAL-LIABILITY-AND-EQUITY> 46,826
<SALES> 9,620
<TOTAL-REVENUES> 9,620
<CGS> (7,937)
<TOTAL-COSTS> (7,937)
<OTHER-EXPENSES> (2,309)
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (812)
<INCOME-PRETAX> (1,331)
<INCOME-TAX> 0
<INCOME-CONTINUING> (1,331)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,331)
<EPS-BASIC> (0.44)
<EPS-DILUTED> (0.44)
</TABLE>
